SSG
BBNX

Summit Securities Group’s Beta Bionics BBNX Stock Holding History

Summit Securities Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,697
Closed -$51.7K – 1448
2025
Q4 		$51.7K Buy
+1,697
New +$45.3K 0.01% 606

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Summit Securities Group's BBNX Position: Q1 2026 in Review

Summit Securities Group sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 1,697 shares — an estimated $51.7K sold.

Summit Securities Group first reported a position in BBNX in Q4 2025 and held it in 1 quarter. The position peaked at $51.7K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Summit Securities Group reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 1,697 Beta Bionics shares in Q1 2026, an estimated $51.7K.
  • Summit Securities Group first reported a position in Beta Bionics in Q4 2025 and held it in 1 quarter.
  • Summit Securities Group's Beta Bionics position peaked at $51.7K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.